The Impact on Survival and Morbidity of Portal–Mesenteric Resection During Pancreaticoduodenectomy for Pancreatic Head Adenocarcinoma: A Systematic Review and Meta-Analysis of Comparative Studies
Open Access
- 20 July 2020
- Vol. 12 (7), 1976
- https://doi.org/10.3390/cancers12071976
Abstract
Background: The literature is conflicting regarding oncological outcome and morbidity associated to portal–mesenteric resection during pancreaticoduodenectomy (PD) in patients with pancreatic head adenocarcinoma (PHAC). Methods: A meta-analysis of studies comparing PD plus venous resection (PD+VR) and standard PD exclusively in patients with adenocarcinoma of the pancreatic head was conducted. Results: Twenty-three cohort studies were identified, which included 6037 patients, of which 28.6% underwent PD+VR and 71.4% underwent standard PD. Patients who received PD+VR had lower 1-year overall survival (OS) (odds radio OR 0.79, 95% CI 0.67–0.92, p = 0.003), 3-year OS (OR 0.72, 95% CI 0.59–0.87, p = 0.0006), and 5-year OS (OR 0.57, 95% CI 0.39–0.83, p = 0.003). Patients in the PD+VR group were more likely to have a larger tumor size (MD 3.87, 95% CI 1.75 to 5.99, p = 0.0003), positive lymph nodes (OR 1.24, 95% CI 1.06–1.45, p = 0.007), and R1 resection (OR 1.74, 95% CI 1.37–2.20, p < 0.0001). Thirty-day mortality was higher in the PD+VR group (OR 1.93, 95% CI 1.28–2.91, p = 0.002), while no differences between groups were observed in rates of total complications (OR 1.07, 95% CI, 0.81–1.41, p = 0.65). Conclusions: Although PD+VR has significantly increased the resection rate in patients with PHAC, it has inferior survival outcomes and higher 30-day mortality when compared with standard PD, whereas postoperative morbidity rates are similar. Further research is needed to evaluate the role of PD+VR in the context of multimodality treatment of PHAC.Keywords
This publication has 70 references indexed in Scilit:
- Pancreaticoduodenectomy Combined with Vascular Resection and Reconstruction for Patients with Locally Advanced Pancreatic Cancer: A Multicenter, Retrospective AnalysisPLOS ONE, 2013
- Vein Involvement During Pancreaticoduodenectomy: Is There a Need for Redefinition of “Borderline Resectable Disease”?Journal of Gastrointestinal Surgery, 2013
- Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 2013
- Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph NodesClinical and Translational Gastroenterology, 2013
- Metaanalysis of trials comparing minimally invasive and open distal pancreatectomiesSurgical Endoscopy, 2010
- Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinomaCancer, 2010
- Prognosis and feasibility ofen-blocvascular resection in stage II pancreatic adenocarcinomaWorld Journal of Gastroenterology, 2010
- Systematic review of outcome of synchronous portal–superior mesenteric vein resection during pancreatectomy for cancerBritish Journal of Surgery, 2006
- Pancreaticoduodenectomy with vascular resection: margin status and survival durationJournal of Gastrointestinal Surgery, 2004